$PULM
Pulmatrix, Inc.

2023 Q4 Form 10-Q Financial Statement

#000149315223040012 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $2.202M $1.753M $1.872M
YoY Change 28.92% -6.36% 75.12%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $911.0K $1.730M $1.685M
YoY Change -41.83% 2.67% 1.75%
% of Gross Profit
Research & Development $3.516M $3.963M $5.287M
YoY Change -21.29% -25.04% 31.32%
% of Gross Profit
Depreciation & Amortization $34.00K $40.00K $41.00K
YoY Change -12.82% -2.44% -10.87%
% of Gross Profit
Operating Expenses $4.427M $5.692M $6.972M
YoY Change -26.62% -18.36% 22.7%
Operating Profit -$3.939M -$5.100M
YoY Change -22.76% -37.73%
Interest Expense $192.0K $220.0K $102.0K
YoY Change 0.52% 115.69% 10100.0%
% of Operating Profit
Other Income/Expense, Net -$50.00K $165.0K $48.00K
YoY Change -39.02% 243.75% 860.0%
Pretax Income -$2.083M -$3.770M -$5.052M
YoY Change -50.59% -25.38% -38.27%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.083M -$3.774M -$5.052M
YoY Change -50.59% -25.3% -38.27%
Net Earnings / Revenue -94.6% -215.29% -269.87%
Basic Earnings Per Share -$1.03 -$1.45
Diluted Earnings Per Share -$0.57 -$1.03 -$1.452M
COMMON SHARES
Basic Shares Outstanding 3.652M shares 3.652M shares 3.478M shares
Diluted Shares Outstanding 3.652B shares 3.478B shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.17M $21.34M $40.68M
YoY Change -46.19% -47.55% -23.94%
Cash & Equivalents $19.17M $21.34M $40.68M
Short-Term Investments
Other Short-Term Assets $742.0K $1.050M $2.066M
YoY Change -39.23% -49.18% 120.26%
Inventory
Prepaid Expenses
Receivables $928.0K $841.0K $476.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $20.84M $23.23M $43.23M
YoY Change -45.36% -46.26% -20.6%
LONG-TERM ASSETS
Property, Plant & Equipment $1.158M $1.166M $265.0K
YoY Change 392.77% 340.0% -76.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $176.0K $217.0K $428.0K
YoY Change -54.76% -49.3% 109.8%
Total Long-Term Assets $13.12M $13.54M $3.225M
YoY Change 367.39% 319.88% 146.18%
TOTAL ASSETS
Total Short-Term Assets $20.84M $23.23M $43.23M
Total Long-Term Assets $13.12M $13.54M $3.225M
Total Assets $33.96M $36.77M $46.45M
YoY Change -17.08% -20.84% -16.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.915M $707.0K $1.155M
YoY Change 61.2% -38.79% 32.0%
Accrued Expenses $1.277M $2.520M $2.748M
YoY Change -48.82% -8.3% 20.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.909M $4.429M $6.324M
YoY Change -22.16% -29.97% 23.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.05M $12.46M $5.080M
YoY Change 149.98% 145.28% -6.32%
Total Long-Term Liabilities $12.05M $12.46M $5.080M
YoY Change 149.98% 145.28% -6.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.909M $4.429M $6.324M
Total Long-Term Liabilities $12.05M $12.46M $5.080M
Total Liabilities $15.96M $16.89M $11.40M
YoY Change 62.16% 48.1% 8.04%
SHAREHOLDERS EQUITY
Retained Earnings -$287.6M -$285.5M -$269.3M
YoY Change 5.16% 6.04%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.00M $19.88M $35.05M
YoY Change
Total Liabilities & Shareholders Equity $33.96M $36.77M $46.45M
YoY Change -17.08% -20.84% -16.68%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$2.083M -$3.774M -$5.052M
YoY Change -50.59% -25.3% -38.27%
Depreciation, Depletion And Amortization $34.00K $40.00K $41.00K
YoY Change -12.82% -2.44% -10.87%
Cash From Operating Activities -$2.015M -$4.140M -$3.604M
YoY Change -60.07% 14.87% 8.82%
INVESTING ACTIVITIES
Capital Expenditures $306.0K $310.0K $0.00
YoY Change 3300.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$306.0K -$310.0K $0.00
YoY Change 3300.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.000K 0.000 1.382M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -2.015M -4.140M -3.604M
Cash From Investing Activities -306.0K -310.0K 0.000
Cash From Financing Activities 3.000K 0.000 1.382M
Net Change In Cash -2.318M -4.450M -2.222M
YoY Change -54.14% 100.27% -34.88%
FREE CASH FLOW
Cash From Operating Activities -$2.015M -$4.140M -$3.604M
Capital Expenditures $306.0K $310.0K $0.00
Free Cash Flow -$2.321M -$4.450M -$3.604M
YoY Change -54.09% 23.47% 12.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001574235
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2022Q1 PULM Stock Issued During Period Value Adjustment Due To Reverse Stock Split
StockIssuedDuringPeriodValueAdjustmentDueToReverseStockSplit
usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
PULM Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
usd
PULM Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
usd
CY2022Q4 PULM Accrued Purchases Of Property And Equipment
AccruedPurchasesOfPropertyAndEquipment
usd
CY2022Q4 PULM Accrued Legal And Patent Current
AccruedLegalAndPatentCurrent
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36199
dei Entity Registrant Name
EntityRegistrantName
PULMATRIX, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1821392
dei Entity Address Address Line1
EntityAddressAddressLine1
36 Crosby Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
dei City Area Code
CityAreaCode
(781)
dei Local Phone Number
LocalPhoneNumber
357-2333
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
PULM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3652285 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21336000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35628000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
153000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
153000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
841000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1298000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
899000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1068000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
23229000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
38147000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1166000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
235000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10686000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
710000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1472000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1472000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
217000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
389000 usd
CY2023Q3 us-gaap Assets
Assets
36770000 usd
CY2022Q4 us-gaap Assets
Assets
40953000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
707000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1188000 usd
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2535000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1638000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
199000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
857000 usd
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
988000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1339000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4429000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5022000 usd
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4038000 usd
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4822000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8422000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
16889000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
9844000 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3652285 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3652285 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3639185 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3639185 shares
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
305395000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
304585000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-285514000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-273476000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
19881000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31109000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36770000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40953000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1753000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1872000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5096000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4363000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3963000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5287000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12002000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13773000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1729000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1685000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5609000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5212000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5692000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
6972000 usd
us-gaap Operating Expenses
OperatingExpenses
17611000 usd
us-gaap Operating Expenses
OperatingExpenses
18985000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3939000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5100000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-12515000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14622000 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
217000 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
102000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
675000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
118000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-52000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-54000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-198000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-116000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
165000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
48000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
477000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3774000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5052000 usd
us-gaap Net Income Loss
NetIncomeLoss
-12038000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14620000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.03
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.03
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.32
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3652285000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3652285000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3478157000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3478157000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3651785000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3651785000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3383171000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3383171000 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31109000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
53000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
296000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4448000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
27010000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
255000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3816000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
23449000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
206000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3774000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
19881000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
47449000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
281000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4973000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
42757000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
277000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4595000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
38439000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
38439000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1382000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
277000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5052000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
35046000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
35046000 usd
us-gaap Net Income Loss
NetIncomeLoss
-12038000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14620000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
96000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
123000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1171000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1033000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
757000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
835000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-8000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-457000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
409000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-169000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1042000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-172000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
428000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-481000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
478000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
233000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1515000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3383000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1007000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1135000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-788000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13974000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14310000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
371000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
77000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-371000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-77000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
53000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1382000 usd
PULM Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts
-152000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1230000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14292000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13157000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37253000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55465000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22961000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42308000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21336000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40683000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
153000 usd
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
153000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1472000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1472000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22961000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42308000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9323000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
664000 usd
PULM Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
1081000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_846_eus-gaap--UseOfEstimates_zIVK27p4wTfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zjR0ntf2P623">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. The most significant estimates and assumptions in the Company’s condensed consolidated financial statements include, but are not limited to, estimates of future expected costs in order to derive and recognize revenue, estimates related to clinical trial accruals and upfront deposits, incremental borrowing rate, and accounting for income taxes and the related valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z7DFsbBVkeye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zY0xuhfhMAu4">Concentrations of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in accounts at a single financial institution that management believes is creditworthy, and the Company has not incurred any losses to date. The Company is exposed to credit risk in the event of default by this financial institution for amounts in excess of the Federal Deposit Insurance Corporation insured limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and nine months ended September 30, 2023, revenue from one customer accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zowXwguq3Pm4" title="Concentration risk percentage"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zwHnl2mvxZE3" title="Concentration risk percentage">100</span></span>% of revenue recognized in the accompanying condensed consolidated financial statements. For the three and nine months ended September 30, 2022, revenue from one customer accounted for approximately <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zZBjuZT1n66d" title="Concentration risk percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zjZzh9ZWa5Nf" title="Concentration risk percentage">99</span></span>% of revenue recognized in the accompanying condensed consolidated financial statements. As of September 30, 2023 and December 31, 2022, one customer accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zQcaY7bkrIhf" title="Concentration risk percentage"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z7KtUyI1kjp8" title="Concentration risk percentage">100</span></span>% of accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> </p>
CY2022Q4 PULM Prepaid Clinical And Consulting
PrepaidClinicalAndConsulting
517000 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
361000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
286000 usd
CY2023Q3 PULM Prepaid Software And Hosting Costs
PrepaidSoftwareAndHostingCosts
83000 usd
CY2022Q4 PULM Prepaid Software And Hosting Costs
PrepaidSoftwareAndHostingCosts
99000 usd
CY2023Q3 PULM Prepaid Clinical And Consulting
PrepaidClinicalAndConsulting
50000 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
405000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
166000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
899000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1068000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2863000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2983000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1697000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2748000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1166000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
235000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
96000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
123000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
904000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1130000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
704000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
475000 usd
CY2023Q3 PULM Accrued Purchases Of Property And Equipment
AccruedPurchasesOfPropertyAndEquipment
664000 usd
CY2023Q3 PULM Accrued Legal And Patent Current
AccruedLegalAndPatentCurrent
49000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
214000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
33000 usd
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2535000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1638000 usd
PULM Agreement Description
AgreementDescription
Pursuant to the Amendment, the Company and Cipla will each initially be responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”). Upon the achievement of each development milestone set forth in the table below, Cipla will reimburse the Company an amount equal to 10% of the cumulative aggregate Direct Costs incurred (each reimbursement referred to as a “Holdback Payment”), potentially bringing the sharing of Direct Costs to a 50/50 basis. If a development milestone is not achieved, the respective Holdback Payment will continue to aggregate and be reimbursed by Cipla to the Company if the Company achieves the subsequent development milestone for that trial set forth in the table below. The Company will share all other development costs with Cipla that are not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis
CY2023Q3 PULM Transaction Costs
TransactionCosts
22000000.0 usd
PULM Warrants Issued Or Exercised
WarrantsIssuedOrExercised
0 shares
PULM Warrants Expired Shares
WarrantsExpiredShares
123310 shares
PULM Warrants Expired Per Shares
WarrantsExpiredPerShares
149.99 shares
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
206000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
277000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
757000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
835000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
4000000.0 usd
us-gaap Reimbursement From Limited Partnership Investment
ReimbursementFromLimitedPartnershipInvestment
2000000.0 usd
CY2023Q3 us-gaap Other Commitment
OtherCommitment
4000000.0 usd
CY2023Q3 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
3800000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
553000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
357000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1349000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1072000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
203000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
206000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
484000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
556000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
756000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
563000 usd
us-gaap Lease Cost
LeaseCost
1833000 usd
us-gaap Lease Cost
LeaseCost
1628000 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
2699000 usd
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
431000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
3562000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1046000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y2M12D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1100 pure
CY2023Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
171000 usd
CY2023Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
1289000 usd
CY2023Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
1326000 usd
CY2023Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
1364000 usd
CY2023Q3 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
1402000 usd
CY2023Q3 PULM Purchase Obligation Due In Fifth Year And After Fifth Year
PurchaseObligationDueInFifthYearAndAfterFifthYear
9154000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14706000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6085000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8621000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
199000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8422000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8621000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1526468000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1526468000 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1592721000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1592721000 shares

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001493152-23-040012-index-headers.html Edgar Link pending
0001493152-23-040012-index.html Edgar Link pending
0001493152-23-040012.txt Edgar Link pending
0001493152-23-040012-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
pulm-20230930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
pulm-20230930_cal.xml Edgar Link unprocessable
pulm-20230930_def.xml Edgar Link unprocessable
pulm-20230930_pre.xml Edgar Link unprocessable
pulm-20230930_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending